TRK Inhibitor Shows Early Promise
- PMID: 26603524
- DOI: 10.1158/2159-8290.CD-NB2015-165
TRK Inhibitor Shows Early Promise
Abstract
Results from a phase I study show that the TRK inhibitor LOXO-101 is well tolerated and effective, with patients whose tumors bear NTRK fusions responding well and durably to this targeted therapy.
©2015 American Association for Cancer Research.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources